Psychopharmacology Bulletin

VOL 56 No. 3

VOL 56 No. 2

This issue features systematic reviews on asenapine in bipolar disorder and naltrexone in alcohol use disorder, emerging research on suzetrigine and clavulanic acid for pain and cocaine use disorder, alongside review articles on antipsychotic risk-benefit profiles and Alzheimer’s pharmacotherapy, and case studies examining treatment-resistant schizophrenia, valproate-induced encephalopathy, and neuropsychiatric management in Fragile X syndrome.

VOL 56 No. 1

This issue features a randomized controlled trial of remotely-delivered adherence enhancement for poorly adherent schizophrenia patients, a review of third- and fourth-generation antipsychotic mechanistic advances, lorazepam-assisted interview evidence in clinical psychiatry, PRN medication impact on aggression in forensic psychiatric patients, integrated pharmacogenetic testing for personalized acute alcoholic hallucinosis treatment, obesity prediction in clozapine and olanzapine patients, psychotropic prescribing differences by smoking status, opioid prescribing trends with co-prescribed antagonists, tramadol utilization patterns, and cases of lamotrigine-induced DRESS syndrome with myelosuppression, glecaprevir/pibrentasvir for PTSD, lorazepam for Kleine-Levin syndrome, chronic diphenhydramine misuse sequelae in an adolescent, and the intersections of fetal alcohol syndrome with autism and mood dysregulation.

VOL 55 No. 4

This issue covers a systematic review of second-generation antidepressant monotherapy for acute bipolar-II depression, OPRM1 polymorphism predicting differential naltrexone response in alcohol use disorder, valproate effects on intracellular calcium signaling, clozapine manicogenic properties and potential mechanisms, gender dysphoria with dissociative identity disorder in autism spectrum disorder, contraception and mood effects, genital dysmorphia as a diagnostic construct, methadone prescribing patterns, THC-positive urine prevalence in chronic opioid therapy, and cases of cannabidiol-induced mania, a pilot adult ADHD trial of SDX/d-MPH, reversible lacosamide interference with ECT, psychogenic speech disorder in an adolescent, and dental student stress comparison.

VOL 55 No. 3

This issue features a review of GLP-1 agonist incretin mimetics as additions to the psychopharmacology armamentarium, quetiapine evidence in pediatric psychiatry, buprenorphine prescribing trends for chronic pain, a Kuwait mental illness disability scale proposal, and cases of clozapine-induced mania-like symptoms in schizophrenia, akinetic mutism following bilateral infarcts with mitral valve fibroelastoma, antipsychotic treatment of autistic shutdowns, methadone-to-buprenorphine-naloxone transition challenges, and electroconvulsive therapy with ketamine and esketamine across a decade of treatment-resistant MDD from adolescence to adulthood.

VOL 55 No. 2

This issue examines SNRI efficacy for fibromyalgia through a comprehensive clinical review, borderline personality disorder self-injury as attachment-seeking with psychopharmacological considerations, Hericium erinaceus supplementation potential in chronic and treatment-resistant schizophrenia, sleep and nicotine vaping interplay in adolescents, unipolar versus bipolar depression correlation with calcium, thyroid, and inflammatory markers, and cases of paliperidone-induced hypothyroidism, hallucinogen-persisting perception disorder in an adolescent, bereavement during TMS for MDD, antipsychotic-associated raised creatine kinase responding to clozapine, meningioma-related catatonia misattributed to autism with anxiety, and combination psychopharmacology in clinical practice.

VOL 55 No. 1

This issue covers catatonia psychopharmacology, pharmacogenomic-based personalized dosing in alcoholic hallucinosis, lithium underutilization in patients of African ancestry with bipolar disorder, macrophage migration inhibitory factor and IL-1β as antidepressant response predictors in major depression, gabapentinoid prescribing patterns in chronic pain, and cases of catatonia resolution following single IV lorazepam challenge, viloxazine for hyperkinetic autism, first-episode psychosis in narcolepsy with cataplexy, and adolescent salt overdose suicide attempt.

VOL 54 No. 4

This issue features a comprehensive review of intravenous magnesium for chronic pain, serotonergic drug development for ADHD reviewing past failures and future directions, stellate ganglion block reviews for PTSD and long COVID symptom management, metabolic syndrome with atypical antipsychotics in a Saudi cross-sectional study, thyroid volume in bipolar disorder patients on lithium prophylaxis, psychopharmacotherapy of pica, and cases of sublingual atropine for clozapine-induced sialorrhea in bipolar disorder and valproate-autism considerations.

VOL 54 No. 3

This issue examines intravenous lidocaine for chronic pain management through a narrative review, neuropsychiatric histaminergic circuit potential with the H3 receptor antagonist pitolisant in Prader-Willi syndrome, naltrexone therapeutic potential across psychopharmacology, symptom severity and medication adherence in adults with bipolar disorder, the Black Book of Psychotropic Dosing and Monitoring, and a case of paliperidone palmitate-induced anismus in an adolescent with schizoaffective disorder.

VOL 54 No. 2

This issue covers clavulanic acid effects on cocaine cue reactivity in addiction-related brain areas through a randomized fMRI pilot study, rivastigmine augmentation for positive, negative, and general psychopathology symptoms in chronic schizophrenia through a randomized controlled trial, clozapine prescribing practices, and cases of high-dose lithium for post-COVID depression with recurrent fevers, sertraline-associated Bell’s palsy, intranasal zolpidem misuse and dependence, vascular neurocognitive disorder with a unique depressive delusion, and corrections to adolescent bipolar adherence findings.

VOL 54 No. 1

This issue features comprehensive reviews of lemborexant for insomnia and solriamfetol for excessive daytime sleepiness, a phase 2 open-label study of intranasal racemic ketamine (SLS-002) in MDD with imminent suicide risk, long-acting injectable antipsychotics and aggression, OCD duration of untreated illness and associated factors, and cases of new-onset prolonged psychosis following synthetic cannabinoid use in an older patient and pregabalin adjunctive therapy for risperidone-induced extrapyramidal syndrome in adolescent schizophrenia.

VOL 53 No. 4

This issue covers psychopharmacological medication preference and autistic traits in ADHD with emotion regulation, 1,4-butanediol misuse consequences, CYP2D6 and CYP3A4 polymorphism relationships to haloperidol concentration in acute alcoholic hallucinosis, treatment-resistant juvenile depression management, beta-blockers for autism, and a case of rhabdomyolysis with hyponatremia from water intoxication in chronic schizophrenia.

VOL 53 No. 3

This issue examines MAOI role reaffirmation in melancholic depression treatment, TMS modus operandi for major depressive disorder, symptom severity and medication adherence in adolescent bipolar disorder, venlafaxine effects on brain size and gene expression in BALB/c mice, and cases of cannabis pen-induced psychosis in a first-time adolescent user, olanzapine-related idiopathic intracranial hypertension in first-episode psychosis, and takotsubo cardiomyopathy from duloxetine-atomoxetine combination in ADHD with comorbid GAD.

VOL 53 No. 2

This issue presents a comprehensive clinical reference on Alzheimer’s disease and dementia guidelines with accompanying tables.

VOL 53 No. 1

This issue provides clinical overviews of ADHD current status and emerging directions, memantine indications in psychiatry, the future of schizophrenia psychopharmacotherapy beyond current atypical antipsychotics, parental depression treatment and offspring gender-related risk reduction, cognitive change sensitivity in Parkinson’s disease, and a case of captagon-associated morbid jealousy.

VOL 52 No. 4

This issue features a randomized controlled trial of omega-3 fatty acids and inositol for pediatric bipolar spectrum disorder, adjunctive pimavanserin for MDD from two phase 3 studies, CYP2D6*4 polymorphism and haloperidol concentration in alcohol-induced psychotic disorders, milnacipran effects on vascular endothelial growth factor in major depression, cluster maintenance TMS clinical audit, pharmacological versus combined depression treatment, pharmacophobia and pharmacophilia impact on medication behaviors in Saudi Arabia, and cases of agomelatine monotherapy for autism and risperidone-associated pancreatitis in a child with ADHD.

VOL 52 No. 3

This issue covers medication adherence support combined with long-acting injectable antipsychotics, CYP2D6 polymorphism correlation with haloperidol efficacy in alcoholic hallucinoses, CYP2C19*17 influence on escitalopram concentration in recurrent depression, premenstrual dysphoric disorder psychopharmacotherapy advances, and cases of lidocaine ineffectiveness suggesting new drug targets, buprenorphine/naloxone discontinuation-induced psychosis in bipolar disorder, lurasidone-associated QTc prolongation in first-episode psychosis, and amphetamine-induced psychosis with sleep deprivation.

VOL 52 No. 2

This issue features commentary on the Hamilton Depression Rating Scale’s continued relevance after six decades, antipsychotic monotherapy reducing inflammatory markers in bipolar disorder, demographic and clinical characteristics of antipsychotic-treated older adults with bipolar disorder from the GAGE-BD database, second-generation antidepressant monotherapy for acute bipolar II depression through a systematic review, the MAOI diet prescriber’s guide, and cases of clozapine for risperidone LAI-related dystonia in an adolescent with intellectual disability, and aripiprazole-methylphenidate-induced trichotieromania in an autistic child.

VOL 52 No. 1

This issue examines inflammatory biomarkers and antidepressant response in MDD through a systematic review and meta-analysis, protein biomarkers for predicting lithium response in bipolar disorder using flow cytometry, suvorexant for insomnia treatment, viloxazine add-on to clozapine-responsive schizophrenia addressing cognitive, negative, and metabolic domains, and cases of risperidone and chlorpromazine-induced stuttering, antipsychotic-induced laryngeal dystonia, and low-dose risperidone for autism with comorbid ARFID and misophonia.

VOL 51 No. 4

This issue covers comprehensive clozapine monitoring practices in Saudi Arabia, clozapine-induced hypertension and autonomic dysfunction, characteristics of inpatients prescribed dopamine receptor blocking agents, obesogenic medications and weight gain in depression from the GUIDED study, oxidative stress mechanisms in psychological trauma, SSRI-nutraceutical combination in MDD, plasma phenazepam concentration influenced by hsa-miR-370-3p and CYP2D6*4, antiepileptic-induced myotoxicity, and dose-dependent sertraline-induced urinary incontinence in OCD.

VOL 51 No. 3

This issue examines regulatory requirements and their role in modest antidepressant clinical trial effects, IV ketamine clinic development for treatment-resistant depression, MDMA for PTSD in adults, ADHD drug holidays and anthropometric changes during methylphenidate treatment, lithium-induced hyperparathyroidism, long-acting injectable antipsychotics and subjectivity in schizophrenia, akathisia pharmacologic management strategies, religiosity and guilt in OCD outcomes, zaleplon for insomnia in HIV-positive patients, and long-acting injectable antipsychotic use in incarcerated youth.

VOL 51 No. 2

This issue covers SPN-812 (viloxazine) phase 3 placebo-controlled data, brexanolone for postpartum depression, brexpiprazole pharmacological review for schizophrenia and MDD, clozapine’s cortical silent period prolongation in treatment-resistant schizophrenia, lamotrigine and Stevens-Johnson syndrome prevention, hyperprolactinemia and infertility in women on antipsychotics, omics-based biomarkers and mirtazapine pharmacokinetics in affective disorders with comorbid alcohol use, a bipolar disorder patient-centered software system, and a case of OCD driven by ritual addiction.

VOL 51 No. 1

This issue examines adverse effects of recreational and medical cannabis, benzodiazepine prescribing risk factors and patterns in a Spanish mental health cohort, omics-based biomarkers influencing fluvoxamine pharmacokinetics in affective disorders with comorbid alcohol use, and an academic psychiatry department’s transition to telepsychiatry during the pandemic.

VOL 50 Supplement No. 1

This supplement focuses on pain medicine, featuring reviews of intravenous lidocaine for postoperative pain, dexmedetomidine for regional blocks, adhesive capsulitis minimally invasive treatments, epidurolysis for epidural adhesions, elagolix for endometriosis pain, spinal cord stimulation with neuromodulating medications, intrathecal morphine for refractory cancer pain, lasmiditan for migraine, oral muscle relaxants for cerebral palsy pain, radiofrequency ablation long-term outcomes, and studies on epidural analgesia in hernia repair, epidural blood patch outcomes, and interventional approaches to cerebral palsy spasticity.

VOL 50 No. 4

This issue presents reviews of oral ketamine efficacy and tolerability in major depression through a systematic review and meta-analysis, asenapine transdermal patch for schizophrenia, cariprazine for schizophrenia and bipolar disorder, lumateperone for schizophrenia treatment, lamotrigine in borderline personality disorder through a systematic review and meta-analysis, patient response trajectories in MDD, and prazosin for substance-related drug dreams in adolescents.

VOL 50 No. 3

This issue features a comprehensive lofexidine update for opioid withdrawal management, naldemedine for opioid-induced constipation, tardive dyskinesia risk factor assessment, CYP2D6 polymorphism impact on duloxetine concentration in MDD, micro-RNA hsa-miR-370-3p influence on mirtazapine concentration in MDD, methamphetamine impact on vancomycin clearance, autism spectrum disorder screening in neonatal encephalopathy, and clozapine use in the general hospital setting.

VOL 50 No. 2

This issue examines antiepileptic drugs and bone health, cannabis use association with psychological disorders, sequential multiple assignment randomized treatment (SMART) design for bipolar disorder, prazosin demographic variation in PTSD sleep disturbance treatment among combat veterans, and cases of autism spectrum disorder with BOR syndrome and intellectual disability with challenging sexual behavior treated with GNRH analogues.

VOL 50 No. 1

This issue covers asenapine in bipolar depression treatment, organic lithium salt effects on oxidative stress markers in bipolar patients, psychiatric prescribing patterns for depression in an outpatient clinic, and cases of low-dose aripiprazole efficacy in 22q11.2 deletion syndrome psychosis, catatonia misdiagnosis, cocaine-induced carotid artery dissection with tongue swelling, and atomoxetine-induced spontaneous ejaculation.

VOL 49 No. 2

This issue examines long-acting injectable antipsychotic primary adherence predictors post-discharge, oral versus long-acting injectable antipsychotic comparison in schizophrenia through a mirror analysis, paliperidone palmitate serum concentration with three-week dosing, lithium revisited for behavioral stabilization in adolescents and adults with autism, ECT for somatic delusions in treatment-resistant schizoaffective disorder, and cases of delayed paliperidone overdose toxicity in adolescent attempted suicide, pregabalin-vitamin D interaction in migraine, and involuntary facial twitching with long-acting injectable olanzapine.

VOL 49 No. 1

This issue covers sub-anesthetic ketamine with ECT in treatment-resistant depression through a double-blind placebo-controlled trial, gabapentin adjunct to benzodiazepines for alcohol withdrawal, paroxetine versus vortioxetine for postmenopausal depressive symptoms, exercise as a treatment for schizophrenia, thrombolytic therapy in cocaine users with ischemic stroke, medication reconciliation impact in outpatient depression care, ketamine’s beneficial effects in refractory depression, cocaine-induced psychosis treated with asenapine, neuroleptic malignant syndrome pharmacotherapy, and risperidone withdrawal-induced akathisia.

VOL 48 No. 4

This issue features a randomized double-blind trial of cariprazine augmentation in MDD, a three-year naturalistic study on early long-acting injectable antipsychotic use in first-episode psychosis, atypical antipsychotic utility in pain medicine, adolescent chronic pain dismissal perspectives, and cases of clozapine-associated hypersexuality, cyclobenzaprine-induced psychosis, and a response to cyclical menstrual psychosis literature.

VOL 48 No. 3

This issue examines long-acting injectable antipsychotic effects on hospital readmission, paroxetine hydrochloride solution titration approaches, cyclical menstrual psychosis with updated literature review, major depressive disorder following dermatomyositis linking depression with inflammation, and cases of concomitant pseudocyesis and Couvade syndrome, progressive non-familial cerebellar degeneration with Hashimoto’s thyroiditis, and risperidone-induced isolated thrombocytopenia.

VOL 48 No. 2

This issue features an updated dosing and monitoring guide for children and adolescents, quetiapine characterization in military PTSD, a pilot evaluation of clinical pharmacy services in ambulatory psychiatry, and a case of pseudoephedrine management for psychotropic-induced stuttering priapism in schizophrenia.

VOL 48 No. 1

This issue covers vortioxetine dose variation across countries relative to antidepressant use patterns, quality of life and functioning analysis in major depression comorbid with medical conditions, and complementary alternative medicine use in children and adolescents with autism spectrum disorder.

VOL 47 No. 4

This issue examines persisting psychosocial impairments in adults treated for ADHD, unmet medication coverage needs in adult ADHD, physical activity and symptomatic decline in chronic schizophrenia through a systematic review, collaborative care content analysis in ambulatory psychiatric pharmacy consultation, and cases of dextromethorphan-induced psychosis and escitalopram-induced SIADH in an elderly patient.

VOL 47 No. 3

This issue presents clinical pharmacology data on aripiprazole lauroxil including phase-1 pharmacokinetic comparison across dose intervals and one-year metabolic and endocrine profiles, alongside four studies on valbenazine (NBI-98854) for tardive dyskinesia covering efficacy in patients with mood disorders, efficacy in schizophrenia and schizoaffective disorder, long-term safety and tolerability, and single-dose and repeat-dose pharmacokinetics in healthy subjects.

VOL 47 No. 2

This issue covers long-acting injectable paliperidone palmitate efficacy and safety, sex differences in antipsychotic-related metabolic functioning in schizophrenia spectrum disorders, amphetamine addition to sedating medication regimens and its impact on reaction time, student pharmacist-driven medication reconciliation in a depression clinic, and cases of aripiprazole-induced asymptomatic hypertension and combined antipsychotics with ECT in treatment-resistant schizophrenia.

VOL 47 No. 1

This issue features a review of post-disaster psychopharmacological interventions to prevent psychiatric sequelae, asenapine for physical aggression control in a naturalistic pilot study, and cases of olanzapine-induced fever, opium withdrawal delirium, valproic acid-induced hyperammonemic encephalopathy in bipolar I disorder, and long QT syndrome management in an adolescent with bipolar disorder.

VOL 46 No. 2

This issue examines adjunctive asenapine for PTSD, paliperidone switching effects after risperidone long-acting injectable discontinuation, lamotrigine maternal and fetal outcomes in pregnancy, autism spectrum disorder treatment in children and adolescents, dextromethorphan as a rapid-acting antidepressant bridging molecule for treatment-resistant depression with antidepressant loss of response, and a case of valproic acid and hepatic steatosis.

VOL 46 No. 1

This issue covers psychotropic pharmacovigilance surveillance in a developing country, a randomized pilot study of quetiapine XR monotherapy and adjunctive therapy in MDD with comorbid GAD, CYP2D6 gene polymorphisms in the Turkish population, paliperidone palmitate in naturalistic outpatient practice, paroxetine safety reappraisal, escitalopram versus fluoxetine comparison for sexual pain in women on antidepressants, and ziprasidone augmentation for adolescent OCD.

VOL 45 No. 1

This issue features a randomized double-blind trial of quetiapine XR monotherapy for MDD, a tribute to Roland Kuhn’s contributions to clinical psychopharmacology, and cases of agomelatine for depression in schizophrenia, antipsychotic inefficacy in premenstrual psychosis, and paroxysmal perceptual alteration as a drug-induced versus schizophrenic phenomenon.

VOL 44 No. 3

This issue covers antipsychotic-induced symptomatic hyperprolactinemia and dopamine agonist safety, anxiety assessment within depression rating scales, clinical predictors of clozapine response in treatment-resistant schizophrenia, rater training challenges in multi-site mood trials, vilazodone safety and tolerability as a novel antidepressant for MDD, and a case of long-acting risperidone in an adolescent with conduct disorder.

VOL 44 No. 2

This issue features a double-blind paliperidone ER trial in schizophrenia, quetiapine XR adjunctive therapy for GAD with prior inadequate treatment response, a randomized adjunctive trial of zonisamide for bipolar depression, and cases of atomoxetine-induced hypothermia, bupropion-induced monoarthritis, and ramelteon for ADHD-related insomnia.

VOL 44 No. 1

This issue examines factors associated with clozapine response in schizophrenia, rating scale standards for schizophrenia clinical trials, test of treatment methodology in psychiatric practice, a randomized adjunctive trial of zonisamide for bipolar mania, and cases of risperidone-fluvoxamine-associated euprolactinemic gynecomastia and clozapine dose-dependent suicidal obsessions.

VOL 43 No. 4

This issue addresses a failed randomized controlled trial of quetiapine XR in acute schizophrenia and its methodological lessons, lamotrigine adjunctive therapy for rapid cycling bipolar depression with recent substance use, metabolic syndrome prevalence across different antipsychotics in a multicentre cross-sectional study, high-dose aripiprazole for treatment-resistant schizoaffective disorder, clozapine-induced sialorrhea treated with trihexyphenidyl, and antidepressant-induced apathy responsive to dose reduction.

VOL 43 No. 3

This issue covers off-label second-generation antipsychotic use for impulse regulation disorders, duloxetine in military PTSD, naltrexone pharmacotherapy for pathological gambling, medication discontinuation patterns in bipolar disorder, the Sex Effects Scale validation, and a case of risperidone-induced ventricular tachycardia.

VOL 43 No. 2

This issue features a meta-analysis of antipsychotic medication in adolescents with schizophrenia, clozapine effectiveness in delaying hospitalization through naturalistic observation, venlafaxine ER treatment with patient education and support in MDD, early improvement as a predictive value in bipolar depression from pooled aripiprazole data, and a case of drug-induced mania in a child with high-functioning autism.

VOL 43 No. 1

This issue examines SSRI pharmacodynamics and beta-1 receptor genotype effects on cardiac vital signs in depressed patients, brain-computer interface effectiveness for ADHD treatment, long-acting injectable risperidone in outpatient naturalistic practice, lithium-divalproex combination predictors in rapid cycling bipolar disorder, signal detection and placebo response parallels between schizophrenia and depression trials, and financial incentives to improve medication adherence in schizophrenia.

VOL 42 No. 4

This issue covers early predictors of olanzapine-induced weight gain from pooled clinical trial data, differential dopaminergic modulation between risperidone and clozapine in substance abuse, controlled-release trazodone efficacy for depressive mood, anxiety, insomnia, and suicidality in MDD, and cases of amisulpride for clozapine-induced sialorrhea, catatonia with CPK elevation in neurosyphilis, and ziprasidone-induced tardive cervical dystonia.

VOL 42 No. 3

This issue features a systematic review of augmentation strategies for major depressive disorder, desvenlafaxine symptom analysis in MDD, tachyphylaxis assessment during venlafaxine ER maintenance treatment, omega-3 fatty acid efficacy in a systematic review and meta-analysis, lamotrigine use in pregnancy and breastfeeding for bipolar disorder, and a case of duloxetine resolving ziprasidone-associated urinary incontinence while improving neuropsychiatric behavior in dementia.

VOL 42 No. 2

This issue examines transcranial magnetic stimulation utility in pharmacoresistant depression, desvenlafaxine and venlafaxine cytochrome P450 and P-glycoprotein inhibition profiles, statistical strategies for detecting differential onset of action in antidepressant trials, MAOI effectiveness reconsidered in bipolar depression, cannabis use and structural hyperconnectivity in recent-onset schizophrenia, and escitalopram-induced hypomania case reports.

VOL 42 No. 1

This issue features a Bayesian signal detection analysis of atypical antipsychotic-associated diabetes in the FDA adverse event database, bipolar-I antimanic prescribing patterns, open-label assessments of aripiprazole for PTSD and memantine for OCD versus GAD, early symptom change as a predictor of depression remission, PTSD neuropsychological functioning following paroxetine treatment, risperidone and hyperacusis in childhood autism, and a case of levomepromazine-induced stuttering.

VOL 41 No. 4

This issue covers exercise efficacy and clinical trial implications for depression treatment, correlates of functioning in bipolar disorder, stimulant-associated mania and hypomania frequency in bipolar disorder, treatment targets in schizophrenia, the REVAMP study rationale combining medication augmentation with psychotherapy, and a report on fluoxetine-induced serotonin syndrome potential in adolescents.

VOL 41 No. 3

This issue addresses prescribing pattern shifts from benzodiazepines to newer antidepressants in anxiety disorders, cocaine as a risk factor for antipsychotic-induced movement disorders, adaptive treatment strategies using substance-induced psychosis as a model, placebo response in depression, psychometric evaluation of a GAD symptom scale, and a randomized trial of extended-release quetiapine fumarate in hospitalized acute schizophrenia.

VOL 41 No. 2

This issue examines the SNRI versus SSRI efficacy controversy, antidepressant onset efficacy methodology, aripiprazole maintenance criteria for bipolar I remission, bipolar depression outpatient treatment quality and costs, glucose testing in patients receiving antipsychotics, CPAP treatment in comorbid sleep apnea and bipolar disorder, and letters addressing clomipramine-aggravated schizophrenia with comorbid OCD.

VOL 41 No. 1

This issue features a pilot trial of bupropion XL versus escitalopram in GAD, guanfacine for PTSD in veterans, duloxetine efficacy relative to prior antidepressant treatment, extended-release carbamazepine switching in acute mania, methylphenidate crossover comparison in ADHD children, the revised dopamine hypothesis of schizophrenia with pharmacological MRI evidence, bipolar pharmacotherapy patterns in elderly adults, a systematic analysis of psychopharmacotherapy in eating disorders, and cases involving cannabis cessation in early schizophrenia, olanzapine pharmacoeconomics, prednisone dependence, aborted neuroleptic malignant syndrome, and methylphenidate-induced photophobia.

VOL 38 Supplement No. 1

This supplement explores advances in anxiety disorder treatment with a focus on atypical antipsychotics, including new drug development roles, early-life adversity and CRF dysregulation in mood and anxiety vulnerability, late-life anxiety disorders, non-human primate models of anxiety, functional brain imaging in psychiatric disorders, and unmet treatment needs in anxiety management.

VOL 40 No. 4

This issue provides reviews spanning fibromyalgia pathophysiology, androgen changes in aging males, cognitive behavioral approaches to pain treatment, genetics in Alzheimer’s disease and schizophrenia, gender differences in schizophrenia, migraine and the limbic system, neuroimaging in schizophrenia, pharmacotherapy of neuropsychiatric syndromes, bipolar spectrum emergence and validation, primary sexual disorders, psychosocial interventions for bipolar disorder within the STEP program, and ethical considerations in schizophrenia treatment and research.

VOL 40 No. 3

This issue features a double-blind randomized trial of adjunctive risperidone for generalized anxiety disorder, a meta-analysis of selegiline transdermal system in depression, bipolar disorder clinical course definitions including response, remission, and recurrence, STEP-BD treatment guideline concordance, complementary and alternative medicine use in bipolar disorder, antipsychotic prescribing patterns in children, neuroimaging of fear and anxiety in PTSD, an open-label tiagabine study in panic disorder, food effects on ziprasidone absorption, psychiatrist antipsychotic switching practices, and antipsychotic influence on suicidal behavior in schizophrenia.

VOL 40 No. 2

This issue covers asenapine clinical trial design for negative symptoms in schizophrenia, long-acting injectable risperidone in special populations, metabolic awareness among psychiatrists treating bipolar disorder, donepezil for post-CABG cognitive decline, bipolar affective puerperal psychosis molecular genetics, alprazolam extended-release versus conventional-tablet onset in panic disorder, signal detection in antidepressant clinical trials, aripiprazole-estrogen drug interaction, lithium-induced nephropathies, aripiprazole monotherapy for chronic PTSD, and cases of reboxetine for induced bruxism and polypharmacy-related EPS in a child.

VOL 40 No. 1

This issue examines drug-drug interactions with second-generation antipsychotics, atypical antipsychotics and pituitary neoplasms in the WHO database, leptin gene polymorphisms and olanzapine-induced weight gain in schizophrenia, citalopram versus amitriptyline in elderly depression, mirtazapine effects on quality of life in elderly depressed patients with comorbidities, treatment characteristics across ethnic groups in the STEP-BD program, current pharmacologic approaches to anxiety disorders, PET imaging of olfactory-induced emotional recall in PTSD, and cases involving fibromyalgia with ADHD, lithium-induced pulmonary hypertension, and CPAP-resolved treatment-refractory psychosis.

VOL 39 No. 1

This issue features a model explaining SSRI therapeutic effects through 5-HT2 receptors, a randomized trial of paroxetine for noncardiac chest pain, randomized crossover comparison of olanzapine and risperidone in schizophrenia, mood stabilizers and atypical antipsychotics as bimodal bipolar treatments, suicide risk analysis in psychotropic versus placebo groups, paroxetine in high-risk suicidal individuals, Yale-Brown OCD Scale validation in schizophrenia, rational evidence-based antidepressant selection, and a case of quetiapine-induced priapism.

VOL 37 Supplement No. 2

This supplement presents a comprehensive review of valproate and divalproex across clinical neuroscience, covering pharmacology, pharmacokinetics, drug interactions, and tolerability, with therapeutic applications in bipolar disorder, epilepsy, migraine, schizophrenia, addictive disorders, and neuropsychiatric conditions in the elderly.

VOL 37 Supplement No. 1

This supplement provides a comprehensive 10-year retrospective on paroxetine, covering its neuropharmacology, pharmacokinetics, drug interactions, and tolerability across controlled-release and immediate-release formulations, with clinical efficacy reviews spanning major depressive disorder, generalized anxiety disorder, panic disorder, PTSD, OCD, social anxiety disorder, perinatal depression, late-life depression, pediatric mood and anxiety disorders, premenstrual dysphoric disorder, menopausal hot flashes, and medically ill patients, alongside neuroimaging correlates of treatment response.

VOL 37 No. 4

This issue examines neuroreceptor imaging applications in psychiatry research, neural circuitry of anxiety through structural and functional neuroimaging, GABA’s role in anxiety pathophysiology and treatment, tryptophan depletion and serotonin in depression, continuation treatment comparing nefazodone and cognitive behavioral analysis in chronic depression, risperidone in elderly neurodegenerative disease management, cholesterol-lowering medication and depression relapse, evidence-based practice methodology, and bupropion sustained release for panic disorder.

VOL 37 No. 3

This issue features clinical studies on cortisol-triggered cocaine craving, citalopram and sertraline comparison in PTSD, tranylcypromine effects on sleep in anergic bipolar depression, IFN-induced depression and NSAID intervention, moclobemide for pain disorder, disturbed glucose metabolism with olanzapine and typical antipsychotics, combined ADHD treatment approaches, olanzapine-fluoxetine combination therapy economics, Homer family proteins at glutamatergic synapses, and evidence-based decision-making in psychopharmacology.

VOL 37 No. 2

This issue explores the glutamate NMDA receptor in Alzheimer’s disease, HPA axis abnormalities and therapeutic implications in Alzheimer’s, functional neuroanatomy of traumatic stress, neurovulnerability and neuroprotection in early psychosis, magnetic resonance spectroscopy of neurotransmission, 5-HT2A promoter polymorphism and olanzapine response in schizophrenia, serotonin and fluoxetine as predictors of depression treatment response, bupropion SR effects on depression symptom clusters, anticonvulsant use during pregnancy, ADHD treatment response metrics, and disulfiram metabolite effects on ethanol-induced locomotor activity.

VOL 37 No. 1

This issue covers isotretinoin’s potential association with depression and suicide, evidence-based treatment of borderline personality disorder, new modeling approaches for bipolar disorder, citalopram safety, pharmacokinetics and drug interactions of sedative hypnotics, intent-to-treat methodology with rescue medication in clinical trials, and a case series of orlistat for psychotropic-induced weight gain.

VOL 36 Supplement No. 3

This supplement examines advances in depression and anxiety disorder management, including gender-specific differences in depression treatment response, long-term antidepressant treatment strategies, late-life depression with comorbid conditions, neurobiology of antidepressant response in anxiety, remission as a critical treatment outcome, and approaches to treatment-resistant depression.

VOL 36 Supplement No. 2

This supplement focuses on optimizing treatment outcomes in depression and generalized anxiety disorder, featuring reviews on antidepressant mechanisms of action, neurobiological advances in anxiety and depression, long-term treatment strategies in affective and anxiety disorders, clinical algorithms for stepped psychiatric care, depression in the elderly, differentiating anxiety from depression, somatic comorbidity management, and the pursuit of remission as a treatment target in mood and anxiety disorders.

VOL 36 Supplement No. 1

This supplement presents a methodological analysis comparing the approaches used to evaluate and compare antidepressant efficacy across clinical trials.

VOL 36 No. 4

This issue features duloxetine for major depressive disorder, glutamatergic system modulators and their implications for mood disorder therapeutics, antidepressant interactions with neurotransmitter transporters and receptors, bipolar disorder management in children and adolescents, cAMP signaling abnormalities in schizophrenia, anticholinergic rating scales in elderly nursing home residents, evidence-based mental health approaches, survival model methodology for psychiatric data, and a case of thyrotoxicosis-induced psychosis.

VOL 36 No. 3

This issue addresses candidate gene studies in eating disorders, monoamine oxidase inhibitor advances, clinical significance of drug binding and displacement interactions, antipsychotic switching from pharmacokinetic and practical perspectives, Ginkgo biloba cognitive effects in healthy populations, citalopram for adolescent anxiety disorders, antipsychotic medications and sudden cardiac death, dietary interventions for psychotropic-induced obesity, and cases involving isopropanol-associated cerebellar dysfunction and Metabolife-induced psychosis.

VOL 36 No. 2

This issue examines neurobiological correlates of borderline personality disorder, magnetic resonance spectroscopy in affective disorders, the Duke geriatric depression treatment algorithm, pharmacotherapy for eating disorders, generalized anxiety disorder diagnosis and pharmacologic management, psychoactive drug interactions with diabetes medications, anticholinergic activity assay utility in research, and tiagabine augmentation for treatment-resistant anxiety disorders.

VOL 36 No. 1

This issue explores P-glycoprotein’s emerging significance in psychopharmacology drug disposition, pharmacokinetics of mood stabilizers and new anticonvulsants, pharmacological applications of MRI, fibromyalgia drug development, lithium in AIDS-related dementia, treatment-refractory ADHD management in children and adolescents, neurobiology of social relationships in social anxiety disorder, stress and hippocampal development in primates, and a case of metoclopramide-induced akathisia with panic and major depression.

VOL 35 No. 4

This issue features a meta-analysis of repetitive transcranial magnetic stimulation for depression, reviews of treatment-refractory mania management, bioelectrical modulators and cell membrane function, ziprasidone and QTc interval considerations, benzodiazepine withdrawal pharmacokinetics, 5-HT1B receptor behavioral implications, central melanocortin signaling in eating disorders, social anxiety disorder, psychopharmacological management in Hispanic Americans, and patient perspectives on mood disorder treatment.

VOL 35 No. 3

This issue covers caffeine pharmacology and its drug interactions in clinical psychopharmacology, therapeutic drug monitoring of antipsychotics, prescribing trends in refractory depression, evidence-based psychosocial treatments for bipolar disorder, the role of inositol and lithium in brain function, premenstrual exacerbations of mood disorders, sexual side effects of conventional and atypical antipsychotics, gender differences in emotional memory processing, cognitive symptoms across the dementia spectrum, and a case of olanzapine-induced neuroleptic malignant syndrome.

VOL 35 No. 2

This issue addresses neuroplasticity impairments in severe mood disorders and their therapeutic implications, clinical trial methodology in Alzheimer’s disease, pharmacokinetic drug interactions between venlafaxine and indinavir, antidepressant drug interaction surveillance, management of treatment-refractory panic disorder, controversies in merging cognitive behavioral and psychopharmacological paradigms, and electroconvulsive therapy for mania in dementia.

VOL 35 No. 1

This issue examines neurodevelopmental models of schizophrenia and pharmacokinetic principles including the second-dose effect, alongside reviews of generalized anxiety disorder neurobiology and treatment, corticosteroid receptor dynamics in stress regulation, nitric oxide pathways in depression, neuroimaging of amygdala function in drug addiction, comorbid OCD and major depressive disorder, and emerging herb-drug interactions with St. John’s Wort.